Winfried F. Pickl, MD, of the Institute of Immunology at the Medical University of Vienna, discusses potential future uses and implications of a novel biomarker to predict responses to chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma.
See part one of the interview on the novel biomarker here.